A Peek Behind the Numbers

A Peek Behind the Numbers

Share this post

A Peek Behind the Numbers
A Peek Behind the Numbers
Debt by Any Other Name

Debt by Any Other Name

An updated look at Teva Pharmaceutical's (TEVA) real leverage profile

Behind the Numbers's avatar
Behind the Numbers
Jun 20, 2023
∙ Paid
3

Share this post

A Peek Behind the Numbers
A Peek Behind the Numbers
Debt by Any Other Name
Share

We wrote about Teva Pharmaceuticals (TEVA) in our April 14, 2022 piece and noted that TEVA was a company many were viewing as a turnaround story. The company had ceased making flawed acquisitions and was devoting itself to fixing the balance sheet by retiring debt. In the last year, TEVA had bounced up and down on various deals to settle opioid lawsuits with several states.

The company has been a treasure trove of accounting distortions that make it difficult to determine what is really going on. We wanted to review the situation again and see if that has changed. Our answer is – Not Really


This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Behind the Numbers
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share